Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fu Fang Dan Hong, commonly known as Danhong Injection, is a standardized Traditional Chinese Medicine (TCM) product derived from the extracts of *Salvia miltiorrhiza* (Dan Shen) and *Carthamus tinctorius* (Hong Hua). It is widely utilized in China for the management of cardiovascular and cerebrovascular conditions, particularly ischemic stroke and coronary heart disease. The formulation is designed to promote blood circulation, resolve blood stasis, and dilate blood vessels. Pharmacologically, it exhibits anti-platelet aggregation, anti-inflammatory, and antioxidant properties, while also providing protection to the vascular endothelium and improving microcirculation. It is typically administered via intravenous infusion in clinical settings.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on danhong injection (Buchang Pharmaceuticals).